Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study Of Pf-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-hodgkin's Lymphoma (Nhl)

Next Previous
Trial Profile

A Phase 1 Study Of Pf-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-hodgkin's Lymphoma (Nhl)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary) ; Utomilumab (Primary)
  • Indications Advanced breast cancer; B-cell lymphoma; Bladder cancer; Chronic lymphocytic leukaemia; Colorectal cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Gastric cancer; Gastrointestinal stromal tumours; Head and neck cancer; Hodgkin's disease; Liver cancer; Lung cancer; Malignant melanoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Nasopharyngeal cancer; Neuroendocrine carcinoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Skin cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man
  • Sponsors Pfizer

Most Recent Events

  • 18 Mar 2022 Results from NCT01307267, NCT02179918 and NCT02444793 comparing the anti drug antibody of utomilumab and its impact on the PK, safety, and efficacy in patients with advanced cancer, presented at the 123rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
  • 06 Mar 2020 Results (n=67) evaluating safety, pharmacokinetics, clinical activity, and pharmacodynamics of treatment with utomilumab plus rituximab in patients with relapsed/refractory follicular (FL) and other CD20(+) non-Hodgkin lymphomas (NHLs) published in the Clinical Cancer Research
  • 19 Mar 2019 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top